Insights: Publications

As Section 101 and the Progeny of *Mayo* and *Myriad* Continue to Wreak Havoc on Portfolios, How Is The Life Sciences Industry Fighting Back?

The Intellectual Property Strategist

JUNE 1, 2019 Written by

Since the U.S. Supreme Court decided *Mayo* and *Myriad*, the Federal Circuit has expanded the holdings and invalidated more patents directed to biological discoveries. If the newly discovered correlations and properties of what is found in nature cannot be patented, what strategies for protection are left for companies doing biological research?